The appointment of Ron Cooper, an experienced biopharmaceutical executive, as the new chairman is likely to be seen positively by investors, indicating strong leadership and strategic direction. The departure of Glenn Dubin may have a neutral to slightly positive impact as it aligns with the company's board evolution strategy.